Latest Regulatory News

Australian Vanadium Limited advances its vertically integrated vanadium strategy with key regulatory approvals, manufacturing expansions, and a new $10 million loan facility, positioning itself for major energy storage projects.

NGX Limited progresses its Malingunde graphite project with key technical studies and downstream qualification, while advancing uranium exploration in Namibia. Market dynamics and regulatory shifts position NGX favorably in the clean energy minerals sector.

Immuron Limited reports progress on its IMM-529 FDA application and a delay in Travelan® clinical trial results due to a U.S. government shutdown, with key data now expected in late November.

NewPeak Metals has completed acquisition of 100% ownership of the Las Opeñas exploration permits in Argentina, with drilling scheduled for early 2026. The company also advances drilling preparations at its Tansey Gold Project in Australia, supported by strong insider buying.

Terrain Minerals has raised $1.17 million through a placement to fund further drilling at its promising Smokebush Project, targeting high-grade gold and silver deposits.

Galan Lithium has completed a $20 million placement and secured Argentine government incentives, advancing its Hombre Muerto West lithium project toward first production in early 2026.

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

Green360 Technologies has independently verified its Eco-Clay product as a high-performance, low-carbon cement substitute made from kaolin waste, poised to disrupt Australia’s $3.5 billion cement market.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.